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Abstract
Despite the use of ionizing radiation (IR) and temozolomide (TMZ), outcome for glioblastoma (GBM) patients
remains dismal. Poly (ADP-ribose) polymerase (PARP) is important in repair pathways for IR-induced DNA damage
and TMZ-induced alkylation at N7-methylguanine and N3-methyldenine. However, optimized protocols for
administration of PARP inhibitors have not been delineated. In this study, the PARP inhibitor ABT-888 was
evaluated in combination with and compared to current standard-of-care in a genetically engineered mouse GBM
model. Results demonstrated that concomitant TMZ/IR/ABT-888 with adjuvant TMZ/ABT-888 was more effective
in inducing apoptosis and reducing proliferation with significant tumor growth delay and improved overall survival
over concomitant TMZ/IR with adjuvant TMZ. Diffusion-weighted MRI, an early translatable response biomarker
detected changes in tumors reflecting response at 1 day post TMZ/IR/ABT-888 treatment. This study provides
strong scientific rationale for the development of an optimized dosing regimen for a PARP inhibitor with TMZ/IR for
upfront treatment of GBM.
Neoplasia (2016) 18, 82–89
Introduction
Glioblastoma (GBM) is the most common and aggressive of
malignant primary brain tumor in adults [1]. Standard-of-care for
newly diagnosed GBM patients includes surgery, irradiation (IR) with
both concurrent and adjuvant temozolomide (TMZ) however the
median survival time for GBM patients is only about 15 months and
the 5-year survival rate is less than 10% [2]. Defects in DNA repair
pathways are known to limit the efficacy of anticancer therapies [3,4]
thus this study was undertaken to evaluate the effects of the
poly(ADP-ribose) polymerase (PARP) inhibitor ABT-888 (Veliparib)
for GBM treatment.
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PARPs are a large family of enzymes with essential roles in DNA
repair, which can render cancer cells resistant to DNA damaging
agents [5]. A number of PARP inhibitors have been or are currently in
development pre-clinically [6] and clinically (NCT00770471,
NCT01514201) [7,8]. When used alone, PARP inhibitors show
high potency in tumors where DNA repair capacity is impaired, such
as deficiency in BRCA genes. Olaparib, a PARP inhibitor, was
recently approved to treat ovarian cancer patients who have BRCA1
and BRCA2 mutations and failed three or more chemotherapy
treatments [9]. Meanwhile, PARP inhibitors used in combination
with DNA damaging interventions achieved optimal therapeutic
results [10].
Concurrent TMZ/IR followed by adjuvant TMZ is standard-of-care
for GBM patients, thus the addition of a PARP inhibitor may provide a
therapeutic benefit. ABT-888 is a potent PARP inhibitor targeting both
PARP-1 and PARP-2, is orally bioavailable and demonstrates blood–
brain barrier penetration [11,12]. ABT-888 has been evaluated in
combination with chemotherapies and/or radiation therapy in several
preclinical studies and early stage clinical trials [13–17].
Assessment and quantification of orthotopic tumor volumes and
growth rates in response to therapy was done using MRI which
allowed for non-invasive assessment of tumors over time. In addition,
diffusion-weighted MRI (DW-MRI) allowed for obtaining informa-
tion related to the microscopic cellular environment of solid tumors
[18]. Since water diffusion values have been shown to be affected by
changes in cellular density, DW-MRI can be consider a surrogate
imaging biomarker for characterizing treatment effects [19].
In this study, a primary GBM genetically engineered mouse model
[20] was used to evaluate if significant therapeutic benefit could be
achieved by the addition of a PARP inhibitor (ABT-888) to TMZ/IR
therapy. MRI was used to quantify and serially follow therapeuti-
c-associated changes in brain tumor volumes and cellularity during
treatment for the dosage groups under evaluation. Overall, results
revealed that inclusion of ABT-888 as part of standard of care therapy
significantly improved the overall outcome of treated mice and
supports clinical evaluation in this context.
Material and Methods
Mouse Glioma Model
A genetically engineered GBM mouse model that recapitulates
defects in the key signaling pathways in GBM, where PDGF is
overexpressed and PTEN is deleted in nestin expressing cells in an
ink4/arf deficient background was used for these studies [21–25]. In
brief, Ntv-a mice were injected i.c. with 104 DF-1 cells transfected
with RCAS-PDGF retroviral vectors within 24 hours post-gestation.
The RCAS/tv-a system generated PDGF-B driven gliomas in
nestin-t-va/ink4a-arf−/−/ptenfl/fl mice which developed tumors with
a 90% to 95% incidence, resulting in the formation of high-grade
gliomas within 4 to 6 weeks post-injection. The model is an attractive
GBM model as tumors share high-grade elements such as
microvascular proliferation, pseudopalisading necrosis and leaky
vasculature with human GBMs [24]. These tumors also closely
mimic the proneural subtype of GBM, in which CDKN2A (encoding
for both p16INK4A and p14ARF) and PTEN deletion are observed
in up to 56% and 69% proneural human gliomas, respectively [26].
In order to dissect the role of ABT-888 in the sensitivity of gliomas to
TMZ and IR, we utilized PDGF-B driven PTEN-deficient and
PTEN-intact gliomas. Mice were monitored daily for symptoms of
tumor development and at 4 weeks of age, mice were screened for
tumors using MRI.
Treatment Protocol
Animals were randomized into treatment groups when MRI-
determined tumor volumes reached 20-30mm3 as measured by
multi-slice MRI. To investigate the efficacies of various combination
and individual therapies, tumor-bearing animals were divided into
eight groups and treated with vehicle (1% DMSO in saline, n = 9),
ABT-888 (25 mg/kg per dose, 2 doses a day, 5 d/wk for 2 weeks, n =
12), TMZ (50mg/kg/day, 5 days/week for 2 weeks, n = 8), IR (1 Gy/
d, 5 d/wk for 2 weeks, n = 13), TMZ/ABT-888 (2 weeks of TMZ/
ABT-888 treatment, n = 8), IR/ABT-888 (2 weeks of ABT-888/IR
treatment, n = 9), TMZ/IR (2 weeks of IR/TMZ treatment followed
by 2 weeks of TMZ treatment, n = 5), and TMZ/IR/ABT-888 (2
weeks of IR/TMZ treatment followed by 2 weeks of TMZ/ABT-888
treatment, n = 6) as shown in Figure 1. Animal care procedures were
approved by the University Committee on Use and Care of Animals
(UCUCA). In late stages of tumor growth, mice may develop
lethargy, weight loss and loss in coordination. If these symptoms
become severe, the animals were euthanized according to approved
UCUCA End Stage Illness Policy and the Tumor Scoring Guidelines.
Ionizing radiation of mice was accomplished at 320 kVp and 10
mA using an IC-320 orthovoltage irradiator (Kimtron Medical,
Bantam, CT). A 6 × 8 cm cone was used at a source-to-surface
distance of 40 cm at a dose rate of ∼138 cGy/min. To ensure proper
calibration of the delivered dose, dosimetry was accomplished using
an ionization chamber connected to an electrometer system that was
directly traceable to a National Institute of Standards and Technology
calibration. Mice were positioned and the whole brain was irradiated
while the rest of the body was shielded using a lead secondary
collimator. In vivo administration of compounds along with radiation
therapy (IR; 1 Gy/day) were administered concurrently daily for 5
days a week over the initial 2-week period.
In order to quantify treatment effects in dosage groups, survival
and progression-free survival times were used as endpoints along with
time-to-progression. Survival was assessed by mice at the time of
reaching the End Stage Illness criteria as outline above. Progression of
mice was determined as the time the tumor volume progressed to the
volume noted for the mouse at the time of treatment initiation
(Figure 2A).
Immunohistochemistry
For ex vivo analysis of tumors, a group of 3 animals per treatment
arm were dosed for the first week cycle and were sacrificed following
the final MR session. Tumors were harvested and fixed in 10%
neutral buffered formalin for a minimum of 48 hours. Tumors were
then sectioned and embedded in paraffin followed by cutting sections
(5-μm) onto glass slides. Paraffin was removed in xylene, and slides
rehydrated using gradually decreasing alcohol concentrations at
2 min/step before ending in tap water (100% ethanol, 95% ethanol,
70% ethanol, water). Slides were then stained using H&E to evaluate
cell viability, a Ki-67 antibody to evaluate for cell proliferation and
ApopTag to quantify apoptosis after antigen retrieval with Diva
(Biocare, Concord, CA) using the Avidin/Biotin Complex System
(Vectastain; Vector Labs, Burlingame, CA) and discolored with the
DAB solution (Vector Labs).
Capture of images was accomplished for both non-treated and
treated brain tumor sections using a digital camera interfaced with an
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Olympus microscope. All images were obtained at the same
magnification. Because of the heterogeneous nature of the tumors,
Ki-67 and apoptosis indices were quantified using the highest staining
area. Briefly, staining was checked under low magnification, and then
the highest staining area was identified from which images were
obtained at 80x magnification. Image analysis was accomplished
using ImageJ to quantify Ki-67–positive and ApopTag-positive cells
and total cell numbers.
Immunoblotting
Tumor tissue from two individual animals from each of the
treatment groups were collected for immunoblotting studies. Tumor
tissues were snap-frozen in liquid nitrogen, and stored at −80°C.
Tissues were then homogenized in NP-40 lysis buffer supplemented
with protease inhibitors and phosphatase inhibitors. Concentration of
protein was determined using Lowry assays (Bio-Rad, Hercules, CA).
Equal amount of protein were loaded in each lane and resolved by 4% to
12% gradient Bis-Tris gel (Invitrogen, CA). Proteins were transferred to
0.2 μm nitrocellulose membrane (Invitrogen, CA). Membranes were
incubated overnight at 4°C with primary antibodies after blocking,
followed by incubation with appropriate HRP-conjugated secondary
antibody at room temperature for one hour. ECL-Plus was used to
detect the activity of peroxidase according to the manufacturer’s
protocol (Amersham Pharmacia, Sweden). Antibodies raised against
PARP-1, pH2A.X(Ser139) were purchased from Cell Signaling
Technology (Beverly,MA). Antibody raised against PARwas purchased
from Trevigen (Gaithersburg, MD). HRP conjugated beta-actin was
purchased from Abcam (Cambridge, MA).
Histological Statistics
Group comparisons of MRI and immunohistologic results were
determined at individual time points using analysis of variance and
least-squares difference to correct formultiple comparisons. Immunologic
differences between groups were assessed using two-tailed Student's t test
in Prism 6 (GraphPad Software, Inc, La Jolla, CA). All other statistical
computations were performed with a statistical software package (SPSS
Software Products, Chicago, IL). Statistical significance was assessed at P
b .05 and all results were presented as means ± SEM.
Imaging Protocols
Groups were followed by MRI to monitor changes in tumor
volumes over time for the first three days and then every other day
until the conclusion of the study. All in vivo MR experiments were
performed on a 9.4 Tesla horizontal bore scanner (Agilent
Technologies, CA). For MRI examination, mice were anesthetized
with isoflurane/air mixture and body temperature was maintained
using a heated air system (Air-Therm Heater; World Precision
Instruments, FL). MR images of mouse brains were obtained using a
two-channel phased array quadrature radio frequency head coil
(Rapid Instruments, Germany). Multi-slice axial images were
acquired by using a spin echo sequence. T2-weighted images through
the brain were produced by using the following parameters: 3 s
repetition time, 48 ms echo time, field of view = 20 × 20 mm using a
256 × 128 matrix, slice thickness = 500 μm, number of slices = 25,
two signal averages per phase encode step. T1-weighted images were
also acquired (TR/TE = 600/17 ms) with similar acquisition
parameters as the T2-weighted scans at 10 minutes post-Gd
administration (100 μl i.p. of ProHance gadoteridol injection
solution) (Bracco Imaging, Germany).
All tumor volumes were quantified using the multi-slice MR
images by electronically outlining the tumor boundary visualized on
T1 Gd-enhanced images in each slice using image processing software
by an individual blinded to the treatment protocol. The number of
tumor pixels was converted to an area by multiplication by the factor
[(field of view)2/(matrix)2]. The total tumor volume was calculated as
the summed area on all slices. Tumor volumes were averaged within
each group and plotted over time.
Diffusion MR scans were used to follow daily changes in tumor
cellular density for 5 days posttreatment initiation. Apparent diffusion
coefficient (ADC) maps were derived from collected images using a
DW spin-echo sequence, equipped with a navigator echo for motion
correction and gradient waveforms sensitive to isotropic diffusion,
with the following parameters: repetition time/echo time = 4000/37
ms, field of view = 20 × 20 mm2, matrix size = 128 × 64, slice
thickness = 0.5 mm, 25 slices, one average, diffusion time = 40 ms,
gradient pulse width = 10 ms, and b values (diffusion weighting) =
120 and 1200 s/mm2. Acquisition time was about 8.5 minutes.
Longitudinal quantification of tumor volumes was accomplished
from volumes of interest contoured along the enhancing tumor rim
using the contrast-enhanced T1-weighted images. Tumor volumes
were used to follow treatment response for the individual treatment
groups. The tumor regions were also used to derive whole-tumor
means of ADC values over time for individual animals. ADC maps
Figure 1. Schematic diagram of treatment schedules. Evaluation of ABT-888, TMZ and IR as monotherapies or combination therapies in a
glioblastomamousemodel. Tumor bearing animals were divided into 8 groups and treated with vehicle (1%DMSO in saline), ABT-888 (25
mg/kg per dose, 2 doses a day, 5 d/wk for 2 weeks), TMZ (50 mg/kg per day, 5 d/wk for 2 weeks), IR (1 Gy/day, 5 d/wk for 2 wk), TMZ/
ABT-888 (2 weeks of TMZ/ABT-888 treatment), IR/ABT-888 (2 weeks of ABT-888/IR treatment), TMZ/IR (2 weeks of IR/TMZ treatment
followed by 2 weeks of TMZ treatment), and TMZ/IR/ABT-888 (2 weeks of IR/TMZ treatment followed by 2 weeks of TMZ/ABT-888
treatment). MRI was used to monitor change in tumor volume every other day.
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were calculated from the two diffusion weightings (b values) using the
following equation:
ADC ¼ ln s1=s2ð Þ= b2−b1ð Þ;
where S1 and S2 are the signal intensities at b values b1 and b2,
respectively, and ADC is the ADC value obtained using b1 and b2.
Voxels that exhibited insufficient signal, which was defined as b10x
noise, in the low b value image (b = 120 s/mm2) were excluded from
the analysis. Response in mean ADC values was assessed by the mean
change from baseline to derive a group mean tumor ADC over a day 5
posttreatment initiation time period. Image reconstruction and digital
image analysis were done using software algorithms developed in
Matlab (The MathWorks, MA).
Data Analysis
Data were presented as mean ± SEM for tumor volume studies.
The group comparisons of the percent change in tumor volume were
performed at individual time points. Statistical comparisons were
made between the control and experimental conditions using the
unpaired two-tailed Student's t test. Overall survival and progression-
free survival were assessed using a Kaplan-Meier analysis with
log-rank test. Statistical significance was assumed at P b .05.
Results
Although PTEN deficiency was shown to cause a homologous
recombination defect and thus sensitization to PARP inhibitors [27],
ABT-888 alone failed to show any anti-tumor effects in this mouse
model (Figure 2A). Both TMZ and radiation monotherapies delayed
did not appear to delay time-to-progression, the treatments did
reduce the tumor growth rate by about 7 days as compared with
vehicle and ABT-888 groups (Figure 2A). Treatment of mice with
IR/ABT-888, TMZ/IR and TMZ/ABT-888 had much more
pronounced tumor growth delays with time-to-progression of 12,
18 and 20 days, respectively (Figure 2A). These results are consistent
with previous reports where ABT-888 was effective as a chemosensi-
tization agent in TMZ sensitive tumors [13]. Compared to all other
groups, treatment with TMZ/IR/ABT-888 provided the longest
time-to-progression (35 days) (Figure 2A) and also substantially
prolonged progression-free survival and overall survival times over the
other treatment groups (Figure 2B, P b .0001 and Figure 2C, P =
.01). The median survival of the TMZ/IR/ABT-88 group was 36.5
days versus 25 days observed in the TMZ/IR group. A previous study
found that concurrent TMZ/IR/ABT-888 showed the trend of
extending overall survival in mice, but the overall survival was not
significant over TMZ/IR treated mice [13]. Our data showed that
concurrent TMZ/IR/ABT-888 with adjuvant TMZ/ABT-888 was
more effective than with concurrent TMZ/IR/ABT-888 alone (data
not shown).
As concurrent TMZ/IR/ABT-888 with adjuvant TMZ/ABT-888
demonstrated the most significant efficacy in delaying tumor
progression among all treatment groups, we compared biological
effects to standard-of-care TMZ/IR and ABT-888 alone. PAR
western blotting of tumor samples collected three days post treatment
initiation are shown in Figure 3. ABT-888 alone greatly reduced the
PAR level compared to the vehicle treated group, demonstrating that
ABT-888 crossed the blood–brain barrier and was highly effective at
suppressing PARP activity. TMZ/IR also decreased PAR level
possibly via DNA damage response pathways while TMZ/IR/
ABT-888 further reduced PAR to non-detectable levels. Levels of
phosphorylation of histone H2Ax, a highly sensitive marker for DNA
damage [28] revealed notable DNA damage, as demonstrated by
elevated phosphorylated H2Ax levels, occurred in TMZ/IR and
TMZ/IR/ABT-888 treated tumors.
Figure 2. Evaluation of ABT-888, temozolomide (TMZ) and ionizing
radiation (IR) as monotherapies or combination therapies in a
glioblastoma mouse model. A, Percentage change of intracerebral
tumor volumes for vehicle treated control, ABT-888, TMZ, IR, TMZ/
ABT-888, IR/ABT-888, TMZ/IR, and TMZ/IR/ABT-888 groups
assessed by MRI as a function of time. Note time-to-progression
occurred at 20 versus 35 days for TMZ/IR and TMZ/IR/ABT-888
groups, respectively. The graph depicts mean ± SEM. Kaplan-
Meier plots for each group are presented for progression-free
survival (B) and overall survival (C).
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To determine the molecular actions of these therapies, whole brain
samples underwent IHC evaluation. Induction of apoptosis was
compared in each group by the numbers of Apoptag foci. As depicted
in Figure 4, A and B, TMZ/IR/ABT-888 elevated the Apoptag level
significantly compared to the other groups demonstrating that TMZ/
IR/ABT-888 was most effective in inducing apoptosis. Cell
proliferation evaluated by measuring Ki67 levels revealed no
significant change for the ABT-888 group compared to vehicle
treated group. TMZ/IR reduced Ki67 levels by 43% while TMZ/IR/
ABT-888 further reduced Ki67 levels by 70% (Figure 4A and B).
These data demonstrate that overall TMZ/IR/ABT-888 was a highly
efficient combination for inducing apoptosis and reducing cellular
proliferation.
In order to facilitate future trials of ABT-888 in clinical practice,
we utilized a quantitative imaging biomarker (apparent diffusion
coefficient (ADC)) derived from diffusion-weighted MRI scans as it is
clinically translatable [18]. Changes in tumor ADC values have been
established as a biomarker for monitoring treatment-induced changes
in tumor cellular density in GBM [29]. ABT-888 alone did not
induce significant change in tumor ADC values (Figure 5, A and B)
which correlated with the trend of increased tumor volumes over time
(Figure 1). TMZ/IR/ABT-888 resulted in a rapid increase (10%) in
Figure 3.Western blot evaluation of PARP activity and DNA damage in post-treatment tumor tissues. Western blotting using antibodies
against PAR, a marker for PARP-1 activity, and pH2Ax, a marker for DNA double strand break. Tumor tissues were harvested from two
animals in each group three days post treatment initiation.
Figure 4. Histopathological analysis of tumor tissue. A, Representative images showing tumor tissue morphology (H&E), apoptosis
(Apoptag) and proliferation (Ki67) in tumor tissues from various groups. B, Percentage of apoptotic cells (Apoptag positive) and
proliferative cells (Ki67 positive) in each group. The graph depicts mean ± SEM.
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tumor ADC values, suggesting increased cell death was initiated
within 1 day following start of treatment (Figure 5). TMZ/IR also
caused elevated ADC values (at 2 days), which also correlated to
tumor growth delay at the early stage of treatment (Figure 2A).
Discussion
In this study, a GBM genetically engineered mouse model was used to
evaluate if administration of a PARP inhibitor would provide
additional therapeutic benefit over TMZ/IR therapy. The mouse
model was chosen in part due to the fact that it responds to TMZ. It is
driven by PDGF that is known to be the initial driver of all gliomas
[30]. EGFR is not amplified in the majority of GBM and when it is, it
activates the same pathways as PDGF. Thus the model used in this
study was an attractive GBM model as generated tumors share
high-grade elements such as microvascular proliferation, pseudopa-
lisading necrosis and leaky vasculature with human GBMs. These
tumors also closely mimic the proneural subtype of GBM, in which
CDKN2A (encoding for both p16INK4A and p14ARF) and PTEN
deletion are observed in up to 56% and 69% proneural human
gliomas, respectively.
We found that in the mouse model used in this study,
administration of ABT-888 alone did not have an appreciable effect
of tumor growth rate (Figure 2A). Both IR and TMZ monotherapies
showed overall similar therapeutic response (Figure 2). However,
when given in concomitant fashion with either IR (IR/ABT-888) or
TMZ (TMZ/ABT-888), additional therapeutic activity was achieved
over IR and TMZ monotherapies (Figure 2A). It is also interesting to
note that both the IR/ABT-888 and TMZ/ABT-888 treatment
groups showed similar response to the TMZ/IR treated group in
terms of tumor growth delay and progression-free survival (Figure 2).
However, the most significant therapeutic response was found in the
TMZ/IR/ABT-888 treatment group. Moreover, the TMZ/IR/
ABT-888 treated group also had the highest percentage of apoptotic
cells and the lowest proliferation signal as measured using Ki67
staining (Figure 4). These results, taken together are very intriguing as
clinically, TMZ/IR is given concomitantly followed by adjuvant
TMZ thus a GBM clinical trial evaluating addition of a PARP
inhibitor along with standard of care (TMZ/IR) appears warranted.
Further work may be needed to evaluate if alternative PARP dosage
schedules could provide similar therapeutic profiles such as
alternating days or weeks, or administration of PARP only
post-TMZ/IR thus concomitant with TMZ (TMZ/ABT-888).
While the latter suggested dosage schedule may seem reasonable as
the combination of TMZ/ABT-888 as an upfront therapy had a
significant therapeutic effect (Figure 2A) therefore adding it following
completion of TMZ/IR may be an alternative strategy. However, in a
recently published randomized phase I/II clinical trial it was reported
that the combination of TMZ and ABT-888 did not significantly
improve 6 month progression-free-survival in recurrent GBM
patients who have been previously treated with TMZ [31]. This
study also helped to establish dosage and schedules for TMZ and
ABT-888 combination therapy which were shown to achieve
tolerable levels of treatment adverse events. The NRG oncology
ROTG group study [31] along our current results using a mouse
GBM, provide an excellent foundation on which to consider
including ABT-888 in upfront newly diagnosed GBM. Literature
supports the possible use of PARP inhibitors to potentiate TMZ
treatment such as in a recent study which showed ABT-888 acted
independently to TMZ sensitivity and could override MGMT(−)
mediated resistance in serum free cultured glioma GBM cell lines
[32]. However, based upon the recent NRG oncology ROTG group
study results, it may be assumed that adding ABT-888 to standard of
care (TMZ/IR) in newly diagnosed patients may be the most prudent
direction to consider assuming a tolerable level of treatment adverse
events can be achieved. Thus a trial investigating tolerability and efficacy
of concomitant TMZ/IR/ABT-888 followed by adjuvant TMZ/
ABT-888 for newly diagnosed GBM should be considered along
with DW-MRI as an early quantitative imaging response biomarker.
Optimization of therapeutic strategies can be aided in preclinical
and clinical settings through the availability of a biomarker for
assessing activity. In this context, we used DW-MRI as an early
quantitative imaging response biomarker for these studies as it has
been found capable of quantifying early effects of antineoplastic
interventions [19,29]. DW-MRI is a sensitive imaging metric capable
of detecting and quantifying treatment-associated alterations in
microscopic tumor cellular structures which impact water movement
Figure 5. A, Representative T1-weighted and ADC images of various groups prior to treatment initiation and 2 days post treatment
initiation. B, Percentage change of mean ADC values for each group. Data is plotted as mean ± SEM.
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within tissue microenvironment [33]. DW-MRI has been reported
useful for early treatment response assessment in glioma patients
[18,34,35]. In the present study, we showed that DW-MRI was
capable of detecting early increases in tumor ADC values at 1–2 days
post-treatment initiation in mice treated with TMZ/IR and TMZ/
IR/ABT-888 which persisted over the 5 days in which they were
monitored by DW-MRI (Figure 5). The increase in tumor diffusion
values indicated that induction of tumor cell death was achieved
which correlated with results presented in Figure 4 which revealed an
increase in apoptosis in TMZ/IR and TMZ/IR/ABT-888 treatment
groups along with an associated decline in proliferation index. Thus,
integration of DW-MRI into a clinical GBM trial involving
evaluation of a PARP inhibitor such as ABT-888 for monitoring
treatment response would provide valuable information for assessing
response and could prove useful in providing additional information
for real time optimization of dose and schedule.
Conclusions
Results presented reveal that inclusion of ABT-888 in combination
with standard of care therapy (TMZ/IR) significantly improved the
overall outcome of GBMmice and supports clinical evaluation in this
context. DW-MRI was also found useful an image-based biomarker
for noninvasive quantification of tumor response. While PARP
inhibitors show promise for improving efficacy of TMZ/IR in GBM,
optimization of dose and schedule to achieve maximal therapeutic
benefit while minimizing hematologic toxicity must be accomplished.
Data presented here provides compelling support for continued
development of a concurrent TMZ/IR/ABT-888 with adjuvant
TMZ/ABT-888 treatment strategy for GBM patients.
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